<DOC>
	<DOCNO>NCT03086343</DOCNO>
	<brief_summary>The comparison safety efficacy ABT-494 versus abatacept participant rheumatoid arthritis stable background conventional synthetic Disease Modifying Anti-Rheumatic Drug ( csDMARD ) inadequate response intolerance biologic DMARDs .</brief_summary>
	<brief_title>A Phase 3 Study Compare ABT-494 Abatacept Subjects With Rheumatoid Arthritis Stable Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs ( csDMARDs ) Who Have Inadequate Response Intolerance Biologic DMARDs</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Diagnosis rheumatoid arthritis ( RA ) &gt; = 3 month . Participants treat &gt; = 3 month &gt; = 1 bDMARD therapy , continue exhibit active RA discontinue due intolerability toxicity , irrespective treatment duration never receive abatacept prior first dose study drug . Participants receive csDMARD therapy &gt; = 3 month stable dose &gt; = 4 week prior first dose study drug . The following csDMARDs allow : methotrexate ( MTX ) , sulfasalazine , hydroxychloroquine , chloroquine , leflunomide . A combination two background csDMARDs allow except combination MTX leflunomide . Meets follow criterion : &gt; = 6 swollen joint ( base 66 joint count ) &gt; = 6 tender joint ( base 68 joint count ) Screening Baseline Visits hsCRP &gt; = 3 mg/L Screening . Prior exposure Janus kinase ( JAK ) inhibitor ( include limit ABT494 , tofacitinib , baricitinib filgotinib ) . Prior exposure abatacept History arthritis onset prior age 17 year current diagnosis inflammatory joint disease RA . Current diagnosis secondary Sjogren 's Syndrome permit Laboratory value meet follow criterion within Screening period prior first dose study drug : serum aspartate transaminase &gt; 2 × upper limit normal ( ULN ) ; serum alanine transaminase &gt; 2 × ULN ; estimate glomerular filtration rate simplify 4variable Modification Diet Renal Disease formula &lt; 40 milli liter ( mL ) /minute/1.73 meter ( ) ^2 ; total white blood cell count &lt; 2,500/micro liter ( μL ) ; absolute neutrophil count &lt; 1,500/μL ; platelet count &lt; 100,000/μL ; absolute lymphocyte count &lt; 800/μL ; hemoglobin &lt; 10 g/ deciliter ( dL ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Arthritis</keyword>
	<keyword>Joint Disease</keyword>
	<keyword>Musculoskeletal Disease</keyword>
	<keyword>Anti-inflammatory agent</keyword>
	<keyword>Antirheumatic agent</keyword>
</DOC>